Astrazeneca (AZN) Inventory Average (2016 - 2026)

Astrazeneca has reported Inventory Average over the past 16 years, most recently at $6.6 billion for Q1 2026.

For Q1 2026, Inventory Average rose 17.5% year-over-year to $6.6 billion; the TTM value through Mar 2026 reached $6.6 billion, up 17.5%, while the annual FY2025 figure was $5.9 billion, 10.58% up from the prior year.
Inventory Average for Q1 2026 was $6.6 billion at Astrazeneca, roughly flat from $6.6 billion in the prior quarter.
Over five years, Inventory Average peaked at $8.3 billion in Q1 2022 and troughed at $4.8 billion in Q1 2023.
A 5-year average of $5.9 billion and a median of $5.6 billion in 2025 define the central range for Inventory Average.
On a YoY basis, Inventory Average climbed as much as 156.81% in 2022 and fell as far as 49.89% in 2022.
Year by year, Inventory Average stood at $4.9 billion in 2022, then grew by 9.6% to $5.4 billion in 2023, then grew by 2.18% to $5.5 billion in 2024, then grew by 20.09% to $6.6 billion in 2025, then dropped by 0.17% to $6.6 billion in 2026.
Business Quant data shows Inventory Average for AZN at $6.6 billion in Q1 2026, $6.6 billion in Q4 2025, and $6.5 billion in Q3 2025.

Peer Comparison